Rationale and design of ARTS: a randomized, double‐blind study of BAY 94‐8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Journal of Heart Failure

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurjhf/hfs061PMID 22562554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aldosterone antagonists for preventing the progression of chronic kidney disease.

  2014cited by this paper
• A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial

  2012cited by this paper
• Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

  2012cited by this paper
• Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.

  2012cited by this paper
• A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

  2011cited by this paper
• CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin–angiotensin–aldosterone system the cornerstone of therapy for systolic heart failure

  2011cited by this paper
• A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.

  2011cited by this paper
• Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium‐Sparing Diuretics

  2011cited by this paper
• Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot)

  2010cited by this paper
• A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule*

  2010cited by this paper
• Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.

  2010cited by this paper
• Aldosterone antagonists for preventing the progression of chronic kidney disease.

  2009cited by this paper
• Mineralocorticoid receptor blockers and chronic kidney disease.

  2009cited by this paper
• The frequency of hyperkalemia and its significance in chronic kidney disease.

  2009cited by this paper
• Use of aldosterone antagonists in heart failure.

  2009cited by this paper
• Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.

  2008cited by this paper
• A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity

  2008cited by this paper
• Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.

  2008cited by this paper
• Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF

  2008cited by this paper
• Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.

  2006cited by this paper
• Mineralocorticoid-receptor blockade, hypertension and heart failure

  2005cited by this paper
• Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

  2002cited by this paper
• Aldosterone in congestive heart failure.

  2001cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Goodman & Gilman's The Pharmacological Basis of Therapeutics

  1985cited by this paper
• The Pharmacological Basis of Therapeutics

  1976cited by this paper
• Antiandrogenic effect of spirolactones: mechanism of action.

  1975cited by this paper
• Aldosterone in congestive heart failure.

  1959cited by this paper

• Mineralocorticoid receptor antagonists in internal medicine practice

  2026cites this paper
• Diabetic kidney disease, biomarkers, and finerenone.

  2026cites this paper
• Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus

  2025cites this paper
• Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists

  2025influential citation
• The interplay between heart failure and chronic kidney disease

  2025cites this paper
• Optimizing Finerenone in People With Diabetes and Chronic Kidney Disease: An Opportunity for the Pharmacist

  2024cites this paper
• An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease

  2024cites this paper
• Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials

  2024cites this paper
• Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

  2024cites this paper
• Finerenone in Heart Failure—A Novel Therapeutic Approach

  2024cites this paper
• Clinical implications of mineralocorticoid receptor overactivation

  2024cites this paper
• Novel drug design and repurposing: An opportunity to improve translational research in cardiovascular diseases?

  2024cites this paper
• Challenges in Diagnosing and Managing the Spectrum of Primary Aldosteronism

  2024cites this paper
• Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes

  2023cites this paper
• Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes

  2023cites this paper
• Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes

  2023cites this paper
• Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist

  2023cites this paper
• Administration of finerenone in chronic kidney disease

  2022cites this paper
• Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

  2022cites this paper
• An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook

  2022cites this paper
• Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus

  2022cites this paper
• Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats

  2022cites this paper
• Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease

  2022cites this paper
• Themed Issue: Emerging Fields for Therapeutic Targeting of the Aldosterone-Mineralocorticoid Receptor Signaling Pathway

  2022influential citation
• Nonsteroidal mineralcorticoid receptor antagonists: Novel therapeutic implication in the management of patients with type 2 diabetes.

  2021cites this paper
• Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials

  2021influential citation
• Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

  2021cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonism for cardiovascular and renal disorders - new perspectives for combination therapy.

  2021cites this paper
• An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension

  2021cites this paper
• Finerenone: First Approval

  2021cites this paper
• Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice

  2021cites this paper
• Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease

  2020cites this paper
• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

  2020cites this paper
• Mineralocorticoid receptor antagonists in patients with chronic kidney disease.

  2020cites this paper
• Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy

  2020cites this paper
• Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

  2020cites this paper
• Advances in the Development of Non-steroidal Mineralocorticoid-receptor Antagonists

  2019cites this paper
• Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

  2019cites this paper
• Mineralocorticoid Receptor Antagonists in the Treatment of Coronary Artery Disease, Myocardial Infarction and Heart Failure

  2019cites this paper
• Mineralocorticoid Antagonism and Diabetic Kidney Disease

  2019cites this paper
• Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro

  2018cites this paper
• Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)

  2018cites this paper
• Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure

  2017cites this paper
• Osthole protects against inflammation in a rat model of chronic kidney failure via suppression of nuclear factor-κB, transforming growth factor-β1 and activation of phosphoinositide 3-kinase/protein kinase B/nuclear factor (erythroid-derived 2)-like 2 signaling.

  2017cites this paper
• Treatment of Hyperkalemia in Heart Failure

  2017cites this paper
• Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.

  2017cites this paper
• 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

  2017influential citation
• Pharmacological interventions for heart failure in people with chronic kidney disease.

  2016cites this paper
• Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis

  2016cites this paper
• Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

  2016cites this paper
• Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1

  2016cites this paper
• Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

  2016cites this paper
• New therapies for arterial hypertension.

  2016cites this paper
• New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?

  2016cites this paper
• New Approaches to Drug Discovery

  2016cites this paper
• Translational In Vivo Models for Cardiovascular Diseases.

  2016cites this paper
• Potential new drug treatments for congestive heart failure

  2016cites this paper
• The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges.

  2016cites this paper
• Aldosterone in vascular and metabolic dysfunction

  2016cites this paper
• Non‐steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease

  2016cites this paper
• Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy

  2015cites this paper
• New approaches in the treatment of hypertension.

  2015cites this paper
• Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).

  2015cites this paper
• Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

  2015influential citation
• Emerging cardiovascular indications of mineralocorticoid receptor antagonists.

  2015cites this paper
• [Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015].

  2015cites this paper
• Outpatient management of chronic heart failure

  2015cites this paper
• Nonsteroidal antagonists of the mineralocorticoid receptor

  2015cites this paper
• Is there a new dawn for selective mineralocorticoid receptor antagonism?

  2014cites this paper
• Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

  2014cites this paper
• Interfering with mineralocorticoid receptor activation: the past, present, and future

  2014cites this paper
• Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure

  2014cites this paper
• Mineralocorticoid receptor modulators: a patent review (2007 – 2012)

  2014cites this paper
• Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review

  2014cites this paper
• Aldosterone antagonists for preventing the progression of chronic kidney disease.

  2014cites this paper
• Therapeutic targets in heart failure: refocusing on the myocardial interstitium.

  2014cites this paper
• Novel Molecular Angiotensin Converting Enzyme and Angiotensin Receptor Imaging Techniques

  2014cites this paper
• Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).

  2013cites this paper
• Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte.

  2013cites this paper
• Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

  2013cites this paper
• Targeting the mineralocorticoid receptor in cardiovascular disease

  2013cites this paper
• The amiloride-sensitive endothelial sodium channel and vascular tone.

  2013cites this paper
• Cardiorenal syndrome: new developments in the understanding and pharmacologic management.

  2013cites this paper
• Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial

  2013cites this paper
• Incidence and Predictors of End-Stage Renal Disease in Outpatients With Systolic Heart Failure

  2013cites this paper
• Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease

  2013cites this paper
• A single-center analysis of guideline-directed medical therapy in patients with heart failure with mildly reduced or preserved ejection fraction according to current heart failure guidelines

  year unknowncites this paper
• Yemen Journal of Medicine

  year unknowncites this paper